{"id":"vancomycin-ci","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"1-5","effect":"Ototoxicity"},{"rate":"10-15","effect":"Red man syndrome (flushing, erythema)"},{"rate":"5-10","effect":"Phlebitis at infusion site"},{"rate":"5","effect":"Fever"},{"rate":"5","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking transglycosylation and transpeptidation reactions essential for cell wall integrity. This leads to cell wall weakening and bacterial cell lysis. It is bactericidal and particularly effective against gram-positive organisms.","oneSentence":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:09.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Clostridium difficile-associated diarrhea and colitis"},{"name":"Endocarditis caused by susceptible strains of streptococci or staphylococci"},{"name":"Septicemia caused by susceptible gram-positive organisms"}]},"trialDetails":[{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT04648696","phase":"PHASE4","title":"Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-03","conditions":"Infection","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glycopeptide antibiotic"],"phase":"marketed","status":"active","brandName":"Vancomycin CI","genericName":"Vancomycin CI","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture. Used for Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea and colitis, Endocarditis caused by susceptible strains of streptococci or staphylococci.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}